Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This letter reports a series of cases where the use of ruxolitinib at a lower dose than previously studied led to hair regrowth in patients with severe alopecia areata.

This review examines the JAK/STAT signaling pathway's significance in inflammatory skin diseases and evaluates the efficacy and safety of oral and topical JAK inhibitors for treating vitiligo and alopecia areata. Results are not reported in this study.

This report documents a novel alanine to valine substitution in the GJB2 gene in a Japanese girl with severe keratitis–ichthyosis–deafness syndrome, suggesting a potential link to her severe recurrent infections and immunodeficiency.

This article discusses Janus kinase inhibitors as a promising future treatment for alopecia areata but does not present new research findings.

This study analyzed screening data from 218 alopecia areata patients before starting Janus kinase inhibitors, revealing the importance of pre-treatment screening due to risks of infections like tuberculosis and hepatitis B, with 74.8% of patients proceeding to treatment in real-world settings.

This study observed that JAK inhibitors were safe and effective for patients with moderate-to-severe alopecia areata and comorbid latent hepatitis B or stable tuberculosis, with careful monitoring and selective prophylaxis.

In this case report, complete hair regrowth was observed in a patient with autoimmune-related alopecia areata after treatment with a Janus kinase inhibitor, suggesting its potential effectiveness for both genetic and sporadic forms of the condition.

This review discusses the potential of JAK inhibitors for treating alopecia areata and reports case study evidence of their effectiveness, but formal clinical trials are needed for more definitive conclusions.

This source reports that the approval of baricitinib and ritlecitinib, which are JAK inhibitors, has marked a significant advancement in treating severe alopecia areata (AA), and suggests that additional treatments with new mechanisms may further improve patient outcomes in the future.

This study observed that individuals with Down syndrome exhibit early immune dysregulation, including multi-organ autoimmunity and hypercytokinemia, and found that the JAK inhibitor tofacitinib showed a good safety profile and reduced skin pathology in a Phase II trial.

This review discusses the evidence supporting Janus kinase inhibitors for alopecia areata and highlights ongoing optimism as phase 3 trials begin, with no new clinical results reported.

This study identified a novel pathogenic splice-site variant of the LAMB3 gene in patients with junctional epidermolysis bullosa, highlighting the importance of gene sequencing for diagnosis.

This article discusses the autoimmune causes of alopecia areata and reports no new clinical results.

In this review, the researchers reported that JAK inhibitors, originally approved by the FDA for other uses, have shown effectiveness in reversing hair loss in patients with moderate to severe alopecia areata, based on current preclinical and clinical studies.

JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.

This review reports that three JAK inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—have gained FDA approval for treating alopecia areata due to their demonstrated efficacy in fostering hair regrowth in clinical trials.

This study identified a new heterozygous mutation in the connexin 26 gene (c.263C>T; p.Ala88Val) in a premature neonate with KID syndrome, who later died from complications.

This study observed that JAK inhibitor therapy may be safely administered to patients with alopecia areata and latent HBV or stable TB, without reactivation of these infections, when appropriate monitoring and prophylaxis are used.

JAK inhibitors may reduce depression risk in alopecia areata patients.

Some JAK inhibitors are effective for significant hair regrowth in alopecia areata.

This study found that KSR1 is essential for v-Ha-ras-mediated skin tumor formation in mice but not for MT-driven mammary tumor genesis, suggesting its potential as a therapeutic target in Ras/MAPK signaling.

This study found that oral JAK inhibitors significantly improve hair regrowth in adults with moderate-to-severe alopecia areata compared to placebo, although they are associated with a higher risk of non-serious adverse events.

This paper creatively examines whether the name "Janus" in Janus kinase inhibitors foreshadows their dual role in the treatment of dermatological conditions, drawing parallels to the Roman god Janus's dual nature and influence over beginnings and transitions.

In this study, pediatric and young adults with alopecia areata reported high satisfaction with oral Janus kinase inhibitors, decreased hair loss severity, and a willingness to continue treatment despite potential risks, citing improvements in hair regrowth, tolerability, quality of life, and mental health.

This review highlights the potential for JAK inhibitors to effectively treat inflammatory and autoimmune skin diseases by targeting the JAK-STAT signaling pathway, advocating for an integrated approach to enhance targeted therapy.

This study assessed the effectiveness of JAK inhibitors in Jordanian patients with alopecia areata, finding that while both tofacitinib and baricitinib improved SALT scores, baricitinib showed greater improvement and a trend towards better hair regrowth, particularly with longer treatment durations.

Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.

In this study, loss of the Notch ligand Jag2 in mouse epidermal cells disrupted early differentiation and affected the structure and behavior of adjacent melanocytes, highlighting Jag2's role in epidermal differentiation and tissue homeostasis.

This study demonstrated that the Alopecia Areata Disease Activity Index (ALADIN), a new biomarker, strongly correlates with treatment response in patients using JAK inhibitors for alopecia areata.